BOSTON, May 18, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined the company as executive vice president and chief financial officer. In t…
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Carla Poulson has joined the company as senior vice president and chief human resources officer. In these roles, Ms. Poulson will be a part of the executive leadership team and provide proactive, strategic leadership and consultation across all company functions. She will also develop and drive initiatives to continue to build company culture and to support the company's business strategy.
Michael D. Price brings more than 25 years of experience in the pharmaceutical industry, including in the rare disease sector BOSTON, May 18, 2020 -- (Healthcare Sales & Marketing Network) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned af... Bi…
Akcea Therapeutics, Inc. (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, May 5 at 4:30 p.m. Eastern Time to discuss its first quarter 2020 financial results and report on pipeline and business progress. Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. All six drugs were discovered by Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology.
Akcea Therapeutics (NASDAQ: AKCA) appointed Carla Poulson as chief human resources officer. Poulson was most recently vice president, senior human resources business partner at Vertex Pharmaceuticals (NASDAQ: VRTX). Her prior experience includes roles at g…
NEW YORK, NY / ACCESSWIRE / April 13, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf of shareholders of Akcea Therapeutics, Inc. (AKCA). Akcea is a development and commercialization company focused on helping patients with serious diseases. In 2010, Ionis entered into a collaboration agreement with Glaxo Group Limited ("GSK"), pursuant to which Ionis would develop inotersen, an antisense drug for the treatment of ATTR amyloidosis ("ATTR"), and GSK would shoulder the research costs and share in the profits after inotersen's commercialization.
NEW YORK, NY / ACCESSWIRE / May 20, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf ...
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined the company as executive vice president and chief financial officer. In this role, Mr. Price will oversee fina…
Needham analyst Chad Messer reiterated a Buy rating on Akcea Therapeutics (NASDAQ:AKCA) Inc on Wednesday, setting a price target of $41, which is approximately 154.34% above the present share price of 16.12.
The FDA defers advisory committee meeting date pertaining to Intercept's (ICPT) NDA for obeticholic acid to treat liver fibrosis due to nonalcoholic steatohepatitis.
Boston, Massachusetts--(Newsfile Corp. - April 10, 2020) - Thornton Law Firm LLP, a law firm that represents shareholders in recovery actions, is investigating potential breach of fiduciary duty claims on behalf of shareholders of Akcea Therapeutics, Inc. (NASDAQ: AKCA). FOR MORE INFORMATION: https://www.tenlaw.com/cases/AKCAAkcea purports to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize products on a global basis. Akcea is a development and commercialization company ...
NEW YORK, NY / ACCESSWIRE / April 23, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf ...
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced The Ministry of Health of Spain (MSCBS) has granted approval for the reimbursement of TEGSEDI® (inotersen) in the treatment of stage 1 or stage…
BOSTON, May 5, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious and rare diseases, today reported financ…
NEW YORK, NY / ACCESSWIRE / April 22, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf ...
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
BOSTON, May 7, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Carla Poulson has joined the company as senior vice president and chief human resources officer. In th…
NEW YORK, NY / ACCESSWIRE / April 29, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf ...
Akcea (AKCA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of 6.67% and -70.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
AKCA earnings call for the period ending March 31, 2020.
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious and rare diseases, today reported financial results for the first quarter ended March 31, 2020. The company reported a net loss for the first quarter ended March 31, 2020 on a GAAP basis of $43 million and on a non-GAAP basis of $36 million. Akcea had $421 million of cash, cash equivalents and short-term investments as of March 31, 2020.
BOSTON, May 14, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced The Ministry of Health of Spain (MSCBS) has granted approval for the reimbursement of TEGSEDI® (inotersen)…
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined the company as executive vice president and chief financial officer. In this role, Mr. Price will oversee financial operations at the company including managing financial strategies and activities related to clinical and regulatory functions, commercial sales, marketing, manufacturing and supply chain.
BOSTON, May 14, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced The Ministry of Health of Spain (MSCBS) has granted approval for the reimbursement of TEGSEDI® (inotersen)…
OTTAWA , May 13, 2020 /CNW/ - Akcea Therapeutics Canada, Inc., a subsidiary of Akcea Therapeutics, Inc. (AKCA), today announced that it has concluded its negotiation with the pan-Canadian Pharmaceutical Alliance (pCPA) with a Letter of Intent regarding TEGSEDI™ (inoterson) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR)1. Akcea Therapeutics, Inc. is a majority-owned affiliate of Ionis Pharmaceuticals, Inc.
Alexion Pharmacueticals CEO Ludwig Hantson has made no secret that he wants to diversify his company’s drug portfolio and he has shown willingness to open the corporate checkbook to accomplish that goal. Last October, Alexion (NASDAQ: ALXN) struck a $930 m…
Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of 6.67% and -70.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
BOSTON (AP) — Akcea Therapeutics Inc. (AKCA) on Tuesday reported a first-quarter loss of $42.9 million, after reporting a profit in the same period a year earlier.
Akcea Therapeutics (NASDAQ:AKCA) has had a great run on the share market with its stock up by a significant 35% over...
BOSTON, MA / ACCESSWIRE / April 15, 2020 / Thornton Law Firm LLP, a law firm that represents shareholders and investors in public companies, announces it is investigating potential claims of breach of ...
With me today are Damien McDevitt, our Chief Executive Officer; Kyle Jenne, our Chief Commercial Officer; and Alex Howarth, our Chief Operating Officer. As a reminder, this conference call includes forward-looking statements regarding the financial look -- outlook for Akcea, Akcea's businesses and the therapeutic and commercial potential of Akcea's products in development.
BOSTON, May 18, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined the company as executive vice president and chief financial officer. In t…
NEW YORK, NY / ACCESSWIRE / May 19, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf ...
BOSTON, May 7, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Carla Poulson has joined the company as senior vice president and chief human resources officer. In th…